keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer bone metastasis

keyword
https://www.readbyqxmd.com/read/28223674/-a-case-of-recurrent-breast-cancer-with-bone-metastasis-successfully-treated-with-everolimus-and-exemestane-therapy
#1
Hidefumi Kubo, Yuta Kimura, Toru Kawaoka, Makoto Miyahara, Ryouichi Shimizu, Yukiko Nagashima, Shigeru Yamamoto, Hiroaki Nagano
We report a case of a patient treated with everolimus and exemestane combination therapy for bone metastasis after breast surgery.The patient, a 58-year-old woman, consulted our department for back pain in October 2014.S he was diagnosed with left breast cancer when she was 41 years old.She had received Bt+Ax for left breast cancer and administered tamoxifen for 5 years.We decided on everolimus and exemestane combination therapy after observing an abnormal uptake in the 7th to 8th thoracic vertebrae on a PET-CT scan...
February 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28210558/bisphosphonate-related-osteonecrosis-of-jaws-in-advanced-stage-breast-cancer-was-detected-from-bone-scan-a-case-report
#2
Prakasit Chirappapha, Saowanee Kitudomrat, Thanaporn Thongjood, Rangsima Aroonroch
Bisphosphonates (BPs) are indicated to treat skeletal-related events (SREs) for cancer patients with bone metastasis. We report a 79-year-old woman with advanced stage breast cancer with bone metastasis who was prescribed BPs (zoledronate), then developed osteonecrosis of jaw. We provide a brief review of the pathogenesis, diagnosis and treatment of this complication.
February 2017: Gland Surgery
https://www.readbyqxmd.com/read/28209986/nf-%C3%AE%C2%BAb-signaling-regulates-cell-autonomous-regulation-of-cxcl10-in-breast-cancer-4t1-cells
#3
Won Jong Jin, Bongjun Kim, Darong Kim, Hea-Young Park Choo, Hong-Hee Kim, Hyunil Ha, Zang Hee Lee
The chemokine CXCL10 and its receptor CXCR3 play a role in breast cancer metastasis to bone and osteoclast activation. However, the mechanism of CXCL10/CXCR3-induced intracellular signaling has not been fully investigated. To evaluate CXCL10-induced cellular events in the mouse breast cancer cell line 4T1, we developed a new synthetic CXCR3 antagonist JN-2. In this study, we observed that secretion of CXCL10 in the supernatant of 4T1 cells was gradually increased during cell growth. JN-2 inhibited basal and CXCL10-induced CXCL10 expression and cell motility in 4T1 cells...
February 17, 2017: Experimental & Molecular Medicine
https://www.readbyqxmd.com/read/28207159/the-critical-role-of-the-znf217-oncogene-in-promoting-breast-cancer-metastasis-to-the-bone
#4
Aurélie Bellanger, Caterina F Donini, Julie A Vendrell, Jonathan Lavaud, Irma Machuca-Gayet, Maëva Ruel, Julien Vollaire, Evelyne Grisard, Balázs Győrffy, Ivan Bièche, Olivier Peyruchaud, Jean-Luc Coll, Isabelle Treilleux, Véronique Maguer-Satta, Véronique Josserand, Pascale A Cohen
Bone metastasis affects more than 70% of patients with advanced breast cancer. However, the molecular mechanisms underlying this process remain unclear. Based on the analysis of clinical datasets, and in vitro and in vivo experiments, we report that the ZNF217 oncogene is a crucial mediator and indicator of bone metastasis. Patients with high ZNF217 mRNA expression levels in primary breast tumours had a higher risk of developing bone metastases. MDA-MB-231 breast cancer cells stably transfected with ZNF217 (MDA-MB-231-ZNF217) displayed the dysregulated expression of a set of genes with bone homing and metastasis characteristics, which overlapped with two previously described "osteolytic bone metastasis" gene signatures, while also highlighting the bone morphogenetic protein (BMP) pathway...
February 16, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28202676/harnessing-the-bmp-signaling-pathway-to-control-the-formation-of-cancer-stem-cells-by-effects-on-epithelial-to-mesenchymal-transition
#5
REVIEW
Ashish Bosukonda, William D Carlson
Cancer stem cells (CSCs) persist in tumors as a distinct population and may be causative in metastasis and relapse. CSC-rich tumors are associated with higher rates of metastasis and poor patient prognosis. Targeting CSCs therapeutically is challenging, since they seem to be resistant to standard chemotherapy. We have shown that a novel peptide agonist of bone morphogenetic protein (BMP) signaling, P123, is capable of inhibiting the growth of primary tumor cells by interacting with type I receptors selectively [activin receptor-like kinase 2 (ALK2) and ALK3, but not ALK6] and type II BMP receptors, activating SMAD 1/5/8 signaling and controlling the cell cycle pathway...
February 8, 2017: Biochemical Society Transactions
https://www.readbyqxmd.com/read/28202531/the-role-of-megakaryocytes-in-breast-cancer-metastasis-to-bone
#6
Walter Jackson, Donna M Sosnoski, Sara E Ohanessian, Paige Chandler, Adam W Mobley, Kacey D Meisel, Andrea M Mastro
Little is known about how megakaryocytes affect metastasis apart from serving as the source of platelets. We noted an increase in the number of megakaryocytes in the femurs of metastases-bearing athymic mice four weeks following intracardiac inoculation of MDA-MB-231 human breast cancer cells. How did the megakaryocytes relate to the metastases? Did megakaryocytes prepare a niche or did they increase in response to metastases? To test these possibilities, we examined two models of experimental metastasis, intracardiac inoculation of human MDA-MB-231 into athymic mice, and intramammary injection of mouse tumor cells, 4T1...
February 15, 2017: Cancer Research
https://www.readbyqxmd.com/read/28197418/expression-of-cadherin-17-promotes-metastasis-in-a-highly-bone-marrow-metastatic-murine-breast-cancer-model
#7
Tomoko Okada, Atsushi Kurabayashi, Nobuyoshi Akimitsu, Mutsuo Furihata
We previously established 4T1E/M3 highly bone marrow metastatic mouse breast cancer cells through in vivo selection of 4T1 cells. But while the incidence of bone marrow metastasis of 4T1E/M3 cells was high (~80%) when injected intravenously to mice, it was rather low (~20%) when injected subcutaneously. Therefore, using 4T1E/M3 cells, we carried out further in vitro and in vivo selection steps to establish FP10SC2 cells, which show a very high incidence of metastasis to lungs (100%) and spines (85%) after subcutaneous injection into mice...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28194325/serum-yb-1-y-box-binding-protein-1-as-a-biomarker-of-bone-disease-progression-in-patients-with-breast-cancer-and-bone-metastases
#8
A R Ferreira, M Bettencourt, I Alho, A L Costa, A R Sousa, A Mansinho, C Abreu, C Pulido, D Macedo, I Vendrell, T R Pacheco, L Costa, S Casimiro
YB-1 (Y-box binding protein 1) is a multifunctional cold-shock protein that has been implicated in all hallmarks of cancer. Elevated YB-1 protein level was associated with poor prognosis in several types of cancers, including breast cancer (BC), where it is a marker of decreased overall survival (OS) and distant metastasis-free survival across all subtypes. YB-1 is also secreted by different cell types and may act as an extracellular mitogen; however the pathological implications of the secreted form of YB-1 (sYB-1) are unknown...
March 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/28194227/bone-metastasis-risk-factors-in-breast-cancer
#9
REVIEW
Catarina Pulido, Inês Vendrell, Arlindo R Ferreira, Sandra Casimiro, André Mansinho, Irina Alho, Luís Costa
Bone is the single most frequent site for bone metastasis in breast cancer patients. Patients with bone-only metastasis have a fairly good prognosis when compared with patients with visceral disease. Nevertheless, cancer-induced bone disease carries an important risk of developing skeletal related events that impact quality of life (QoL). It is therefore particularly important to stratify patients according to their risk of developing bone metastasis. In this context, several risk factors have been studied, including demographic, clinicopathological, genetic, and metabolic factors...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28188075/bisphosphonate-related-osteonecrosis-and-metastasis-within-the-same-site-of-the-jaw
#10
Alessandro Corsi, Claudio Ungari, Mara Riminucci, Alessandro Agrillo
Bisphosphonates (BPs) bind selectively to hydroxyapatite and accumulate in sites of active bone remodeling, where they inhibit bone turnover by interfering with osteoclastic recruitment, activity, and survival. For this reason, they are used in oncologic patients to prevent, decrease, and delay potentially life-threatening skeletal-related complications associated with multiple myeloma (MM) and metastasis, including hypercalcemia, pain, and pathologic fractures. Despite substantial benefits, treatment with BPs can be associated with the development of osteonecrosis of the jaw (ONJ), a pathologic condition for which pathophysiologic mechanisms are not completely defined and current criteria for prevention, diagnosis, and management are based largely on expert recommendations and guidelines...
January 18, 2017: Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/28176627/a-review-of-ruthenium-complexes-activities-on-different-steps-of-the-metastatic-process-in-breast-cancer-cells
#11
Cecília Patrícia Popolin, Márcia Regina Cominetti
Cancer is one of the main causes of death worldwide. Breast cancer is the most prevalent type of cancer in women and the leading cause of cancer deaths due to its high metastasis to the lymph nodes, lungs bones and brain. Interactions with the stromal microenvironment surrounding tumor cells facilitate tumor cell migration and invasion of tissues and dissemination to other organs, to form metastasis. The development of antitumor metal-based drugs was originated with the discovery of cisplatin, however, its severe side effects represent a limitation for its clinical use...
6, 2017: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/28174654/breast-cancer-with-extensive-bone-metastasis-mimicking-myeloma
#12
Ya-Ting Hsu, Kung-Chao Chang
Punched-out lesions in skull film usually elicit consideration of myeloma. However, some other diseases cause similar clinical presentations. We describe an uncommon presentation of breast cancer, which mimics multiple myeloma. Therefore, in a broad spectrum of clinical settings, physicians should always consider differential diagnosis and await for definitive pathological diagnosis.
February 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28161871/the-role-of-tgf%C3%AE-in-bone-muscle-crosstalk
#13
REVIEW
Jenna N Regan, Trupti Trivedi, Theresa A Guise, David L Waning
PURPOSE OF REVIEW: The role of bone-derived factors in regulation of skeletal muscle function is an important emerging aspect of research into bone-muscle crosstalk. Implications for this area of research are far reaching and include understanding skeletal muscle weakness in cancer, osteoporosis, cachexia, rare diseases of bone, and aging. RECENT FINDINGS: Recent research shows that bone-derived factors can lead to changes in the skeletal muscle. These changes can either be anabolic or catabolic, and we focus this review on the role of TGFβ in driving oxidative stress and skeletal muscle weakness in the setting of osteolytic cancer in the bone...
February 4, 2017: Current Osteoporosis Reports
https://www.readbyqxmd.com/read/28152812/real-world-treatment-patterns-and-outcomes-in-her2-positive-mbc-patients-with-brain-metastasis-in-the-u-s-community-oncology-setting
#14
Eileen Fonseca, Bongin Yoo, Thomas Wilson, Hans-Peter Goertz, Catherine Lai
: 92 Background: Patients (pts) with HER2 positive (HER2+) metastatic breast cancer (MBC) have different patterns of disease and treatment (tx) from HER2 negative MBC. Brain metastasis (BM) frequently occurs and txs vary. METHODS: This retrospective study included adult HER2+ MBC pts from a community oncology network electronic health record (EHR) database and diagnosed between 2009-2011, with follow-up until 11/2014. Pts with other primary tumors were excluded...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28143986/expression-of-biomarkers-cxcr4-il11-ra-tff1-mlf1p-in-advanced-breast-cancer-patients-with-bone-metastatic-a-diagnostic-study
#15
Cosphiadi Irawan, Djumhana Atmakusumah, Nurjati Chaeranie Siregar, The Bin Tean, Lim Weng Kong, Ong Choon Kiat, Abdulmuthalib Abdulmuthalib, Alida Harahap, Muchtaruddin Mansyur
AIM: to analyze expression of biomarkers CXCR4, IL11-RA, TFF1 and MLF1P, and clinicopathology in advanced breast cancer patients with bone metastatic. METHODS: this is a cross-sectional study. Analysis was done against a total of 92 breast cancer patients, including 46 bone metastatic patients and 46 non-bone metastatic patients. Immunohistochemistry and microarray analysis was performed in 81 formalin fixed paraffin embedded (FFPE) samples from 81 patients were used...
October 2016: Acta Medica Indonesiana
https://www.readbyqxmd.com/read/28133220/-a-case-of-her2-positive-breast-cancer-treated-with-nipple-sparing-mastectomywith-immediate-reconstruction-using-a-tissue-expander-after-nab-paclitaxel-combined-with-chemotherapy
#16
Ayami Nonomura, Naoki Aomatsu, Seika Tei, Goichi Haraoka, Gen Tsujio, Yoshihito Yamakoshi, En Wang, Daisuke Nagashima, Toshiki Hirakawa, Takehiko Iwauchi, Takafumi Nishii, Junya Morimoto, Kazunori Nakazawa, Yasutake Uchima, Kazuhiro Takeuchi
A 59-year-old woman presented to our hospital with a mass in her left breast. Mammography and ultrasound showed a 9 ×11×12mm mass in her left breast, and left axillary lymph adenopathy. Core needle biopsy and pathological examination confirmed the diagnosis of ER-negative, PgR-negative, HER2-positive invasive ductal carcinoma with axillary lymph metastasis. Dynamic computed tomography(CT)and bone scintigraphy showed no metastasis. A diagnosis ofbreast cancer with stage II A(T1N1M0)was made, and we started neoadjuvant chemotherapy...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28125763/continued-treatment-effect-of-zoledronic-acid-dosing-every-12-vs-4-weeks-in-women-with-breast-cancer-metastatic-to-bone-the-optimize-2-randomized-clinical-trial
#17
Gabriel N Hortobagyi, Catherine Van Poznak, W Graydon Harker, William J Gradishar, Helen Chew, Shaker R Dakhil, Barbara B Haley, Nicholas Sauter, Ramon Mohanlal, Ming Zheng, Allan Lipton
Importance: Zoledronic acid, a potent bisphosphonate, is commonly administered to patients with bone metastases to reduce the risk of skeletal-related events (SREs). However, there have been concerns regarding its long-term monthly administration. Objective: To examine whether zoledronic acid every 12 weeks was noninferior to zoledronic acid every 4 weeks in patients with metastatic breast cancer that involved the bone who had previously received a standard dosing regimen of zoledronic acid and/or pamidronate disodium...
January 26, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28123075/ron-kinase-a-target-for-treatment-of-cancer-induced-bone-destruction-and-osteoporosis
#18
Kelsi Andrade, Jaime Fornetti, Ling Zhao, Scott C Miller, R Lor Randall, Neysi Anderson, Susan E Waltz, Mark McHale, Alana L Welm
Bone destruction occurs in aging and numerous diseases, including osteoporosis and cancer. Many cancer patients have bone osteolysis that is refractory to state-of-the-art treatments, which block osteoclast activity with bisphosphonates or by inhibiting the receptor activator of nuclear factor κB ligand (RANKL) pathway. We previously showed that macrophage-stimulating protein (MSP) signaling, which is elevated in about 40% of breast cancers, promotes osteolytic bone metastasis by activation of the MSP signaling pathway in tumor cells or in the bone microenvironment...
January 25, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28114279/the-sigmar1-chaperone-drives-breast-and-colorectal-cancer-cell-migration-by-tuning-sk3-dependent-ca-2-homeostasis
#19
M Gueguinou, D Crottès, A Chantôme, R Rapetti-Mauss, M Potier-Cartereau, L Clarysse, A Girault, Y Fourbon, P Jézéquel, C Guérin-Charbonnel, G Fromont, P Martin, B Pellissier, R Schiappa, E Chamorey, O Mignen, A Uguen, F Borgese, C Vandier, O Soriani
The remodeling of calcium homeostasis contributes to the cancer hallmarks and the molecular mechanisms involved in calcium channel regulation in tumors remain to be characterized. Here, we report that SigmaR1, a stress-activated chaperone, is required to increase calcium influx by triggering the coupling between SK3, a Ca(2+)-activated K(+) channel (KCNN3) and the voltage-independent calcium channel Orai1. We show that SigmaR1 physically binds SK3 in BC cells. Inhibition of SigmaR1 activity, either by molecular silencing or by the use of sigma ligand (igmesine), decreased SK3 current and Ca(2+) entry in breast cancer (BC) and colorectal cancer (CRC) cells...
January 23, 2017: Oncogene
https://www.readbyqxmd.com/read/28114269/a-ror1-her3-lncrna-signalling-axis-modulates-the-hippo-yap-pathway-to-regulate-bone-metastasis
#20
Chunlai Li, Shouyu Wang, Zhen Xing, Aifu Lin, Ke Liang, Jian Song, Qingsong Hu, Jun Yao, Zhongyuan Chen, Peter K Park, David H Hawke, Jianwei Zhou, Yan Zhou, Shuxing Zhang, Han Liang, Mien-Chie Hung, Gary E Gallick, Leng Han, Chunru Lin, Liuqing Yang
Bone metastases remain a serious health concern because of limited therapeutic options. Here, we report that crosstalk between ROR1-HER3 and the Hippo-YAP pathway promotes breast cancer bone metastasis in a long noncoding RNA-dependent fashion. Mechanistically, the orphan receptor tyrosine kinase ROR1 phosphorylates HER3 at a previously unidentified site Tyr1307, following neuregulin stimulation, independently of other ErbB family members. p-HER3 Tyr1307 recruits the LLGL2-MAYA-NSUN6 RNA-protein complex to methylate Hippo/MST1 at Lys59...
January 23, 2017: Nature Cell Biology
keyword
keyword
67814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"